Q3 2025 · 13F-HR
Foresite Capital Management V, LLCholdings as filed
Filed 2025-11-14 · accession 0001104659-25-112503
$108.7M
Reported value
6
Positions
2025-09-30
Period end
The Brief · Foresite Capital Management V, LLC · Q3 2025
AI · grounded in 13F
Foresite Capital Management V, LLC trimmed its position in Maze Therapeutics, Inc. MAZE by 75.002%. The fund accumulated shares of Lyell Immunopharma, Inc. LYEL, increasing the position by 17.3185%. Total assets under management stood at $108,743,611 across six positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG Oncology, Inc. | $40.4M | 37.2% | 1,004,050 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC. | $23.1M | 21.2% | 5,779,348 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $19.8M | 18.2% | 299,069 | Common | SOLE |
| 433000106 | HIMS | Hims & Hers Health, Inc. | $15.5M | 14.2% | 273,151 | Common | SOLE |
| 55083R203 | LYEL | Lyell Immunopharma, Inc. | $7.7M | 7.12% | 477,078 | Common | SOLE |
| 578784100 | MAZE | Maze Therapeutics, Inc. | $2.2M | 2.06% | 86,291 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.